Clinical Trial

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-03.
Status change: Not Yet Recruiting → Recruiting 2025-11-30
Trial Details
NCT Number NCT06758700
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Collaborators: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD
Conditions Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases
Enrollment 15 participants
Start Date 2025-02-07
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-05